|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
|
EP0359096B1
(en)
|
1988-09-15 |
1997-11-05 |
The Trustees Of Columbia University In The City Of New York |
Antibodies having modified carbohydrate content and methods of preparation and use
|
|
JP2650358B2
(ja)
|
1988-10-06 |
1997-09-03 |
株式会社ニコン |
半透過部材を有する光学装置
|
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
|
CA2018248A1
(en)
|
1989-06-07 |
1990-12-07 |
Clyde W. Shearman |
Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
|
|
US5622929A
(en)
*
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
|
US5837821A
(en)
|
1992-11-04 |
1998-11-17 |
City Of Hope |
Antibody construct
|
|
US5792456A
(en)
*
|
1994-08-04 |
1998-08-11 |
Bristol-Myers Squibb Company |
Mutant BR96 antibodies reactive with human carcinomas
|
|
ES2167391T3
(es)
*
|
1994-09-16 |
2002-05-16 |
Merck Patent Gmbh |
Inmunoconjugados ii.
|
|
GB9422383D0
(en)
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
|
WO1996040662A2
(en)
|
1995-06-07 |
1996-12-19 |
Cellpro, Incorporated |
Aminooxy-containing linker compounds and their application in conjugates
|
|
US5989830A
(en)
|
1995-10-16 |
1999-11-23 |
Unilever Patent Holdings Bv |
Bifunctional or bivalent antibody fragment analogue
|
|
GB9524973D0
(en)
|
1995-12-06 |
1996-02-07 |
Lynxvale Ltd |
Viral vectors
|
|
SE9601245D0
(sv)
|
1996-03-29 |
1996-03-29 |
Pharmacia Ab |
Chimeric superantigens and their use
|
|
EP0888125B1
(en)
*
|
1996-03-20 |
2004-05-26 |
Immunomedics, Inc. |
GLYCOSYLATED IgG ANTIBODIES
|
|
ATE386809T1
(de)
|
1996-08-02 |
2008-03-15 |
Bristol Myers Squibb Co |
Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
WO1999022764A1
(en)
|
1997-10-31 |
1999-05-14 |
Genentech, Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
|
US6953675B2
(en)
*
|
1997-11-06 |
2005-10-11 |
Immunomedics, Inc. |
Landscaped antibodies and antibody fragments for clinical use
|
|
US6001817A
(en)
*
|
1998-01-12 |
1999-12-14 |
Unitech Pharmaceuticals, Inc. |
Pharmaceutical composition comprised of cisplatin, and processes for making and using same
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
ES2292236T3
(es)
|
1998-04-02 |
2008-03-01 |
Genentech, Inc. |
Variantes de anticuerpos y sus fragmentos.
|
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
EP1105427A2
(en)
|
1998-08-17 |
2001-06-13 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
|
US6465612B1
(en)
|
1998-09-23 |
2002-10-15 |
The Regents Of The University Of California |
Synthetic peptides, conjugation reagents and methods
|
|
EP1006183A1
(en)
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Recombinant soluble Fc receptors
|
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
HU230769B1
(hu)
|
1999-01-15 |
2018-03-28 |
Genentech Inc. |
Módosított effektor-funkciójú polipeptid-változatok
|
|
US20020102208A1
(en)
|
1999-03-01 |
2002-08-01 |
Paul Chinn |
Radiolabeling kit and binding assay
|
|
CN1110322C
(zh)
*
|
1999-07-21 |
2003-06-04 |
中国医学科学院医药生物技术研究所 |
单克隆抗体Fab'－平阳霉素偶联物及其抗肿瘤作用
|
|
CA2410551A1
(en)
|
2000-06-30 |
2002-01-10 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) |
Heterodimeric fusion proteins
|
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
|
US20050107595A1
(en)
*
|
2001-06-20 |
2005-05-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
MXPA05000511A
(es)
|
2001-07-12 |
2005-09-30 |
Jefferson Foote |
Anticuepros super humanizados.
|
|
US6900292B2
(en)
|
2001-08-17 |
2005-05-31 |
Lee-Hwei K. Sun |
Fc fusion proteins of human erythropoietin with increased biological activities
|
|
US7226903B2
(en)
*
|
2001-10-10 |
2007-06-05 |
Neose Technologies, Inc. |
Interferon beta: remodeling and glycoconjugation of interferon beta
|
|
US7696163B2
(en)
*
|
2001-10-10 |
2010-04-13 |
Novo Nordisk A/S |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
|
US7214660B2
(en)
*
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
|
EP2042196B1
(en)
|
2001-10-10 |
2016-07-13 |
ratiopharm GmbH |
Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
|
|
US7265084B2
(en)
*
|
2001-10-10 |
2007-09-04 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
|
US7795210B2
(en)
*
|
2001-10-10 |
2010-09-14 |
Novo Nordisk A/S |
Protein remodeling methods and proteins/peptides produced by the methods
|
|
US7173003B2
(en)
*
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
|
CA2756610C
(en)
|
2001-10-29 |
2015-08-25 |
Crucell Holland B.V. |
Methods for producing proteins having n-linked glycans comprising (sialyl-) lewis x or lacdinac structures
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
CA2478011C
(en)
|
2002-03-01 |
2013-05-21 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20070207142A1
(en)
*
|
2002-05-08 |
2007-09-06 |
Genentech, Inc. |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
|
EP1534335B9
(en)
|
2002-08-14 |
2016-01-13 |
Macrogenics, Inc. |
Fcgammariib-specific antibodies and methods of use thereof
|
|
WO2004029207A2
(en)
|
2002-09-27 |
2004-04-08 |
Xencor Inc. |
Optimized fc variants and methods for their generation
|
|
DE60334141D1
(de)
|
2002-10-15 |
2010-10-21 |
Facet Biotech Corp |
VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
|
|
JP2006524039A
(ja)
|
2003-01-09 |
2006-10-26 |
マクロジェニクス，インコーポレーテッド |
変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
|
|
EP2055189A1
(en)
*
|
2003-04-09 |
2009-05-06 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
|
MXPA05013565A
(es)
|
2003-06-12 |
2006-03-09 |
Lilly Co Eli |
Proteinas de fusion analogas al glp-1.
|
|
CN1871259A
(zh)
|
2003-08-22 |
2006-11-29 |
比奥根艾迪克Ma公司 |
具有改变的效应物功能的经改进的抗体和制备它的方法
|
|
RU2392324C2
(ru)
|
2003-09-18 |
2010-06-20 |
Симфоген А/С |
Способ связывания интересующих последовательностей
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
US7498298B2
(en)
*
|
2003-11-06 |
2009-03-03 |
Seattle Genetics, Inc. |
Monomethylvaline compounds capable of conjugation to ligands
|
|
WO2005047327A2
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
|
|
US7001978B2
(en)
|
2003-11-19 |
2006-02-21 |
Xerox Corporation |
Unsaturated ester substituted polymers with reduced halogen content
|
|
CA2548817A1
(en)
|
2003-12-04 |
2005-06-23 |
Xencor, Inc. |
Methods of generating variant proteins with increased host string content and compositions thereof
|
|
US20050249723A1
(en)
|
2003-12-22 |
2005-11-10 |
Xencor, Inc. |
Fc polypeptides with novel Fc ligand binding sites
|
|
US7338933B2
(en)
*
|
2004-01-08 |
2008-03-04 |
Neose Technologies, Inc. |
O-linked glycosylation of peptides
|
|
CA2552788C
(en)
|
2004-01-12 |
2013-09-24 |
Applied Molecular Evolution, Inc. |
Fc region variants
|
|
EP1737890A2
(en)
|
2004-03-24 |
2007-01-03 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
ES2339953T5
(es)
|
2004-05-04 |
2020-05-06 |
Novo Nordisk Healthcare Ag |
Glicoformas de factor VII ligadas a O y método de fabricación
|
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
|
CN103172731A
(zh)
|
2004-07-15 |
2013-06-26 |
赞科股份有限公司 |
优化的Fc变体
|
|
KR101270829B1
(ko)
*
|
2004-09-23 |
2013-06-07 |
제넨테크, 인크. |
시스테인 유전자조작 항체 및 접합체
|
|
US20060084145A1
(en)
|
2004-09-27 |
2006-04-20 |
Anderson Glenn M |
sRAGE mimetibody, compositions, methods and uses
|
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
|
JP4829609B2
(ja)
|
2004-12-22 |
2011-12-07 |
独立行政法人科学技術振興機構 |
ヒト抗体酵素およびその生産方法
|
|
CN101160326B
(zh)
|
2005-02-23 |
2013-04-10 |
利普生技术有限公司 |
用于蛋白质衍生和缀合的活化的唾液酸衍生物
|
|
AU2006230099B2
(en)
|
2005-03-25 |
2012-04-19 |
Gitr, Inc. |
GITR binding molecules and uses therefor
|
|
JP2008537941A
(ja)
*
|
2005-03-31 |
2008-10-02 |
ゼンコー・インコーポレイテッド |
最適化特性を有するＦｃ変異体
|
|
CA2602663A1
(en)
|
2005-03-31 |
2006-10-05 |
Xencor, Inc. |
Fc variants with optimized properties
|
|
WO2006130834A2
(en)
|
2005-05-31 |
2006-12-07 |
Board Of Regents, The University Of Texas System |
IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
|
|
ES2547463T3
(es)
|
2005-06-17 |
2015-10-06 |
Merck Sharp & Dohme Corp. |
Moléculas de unión a ILT3 y usos de las mismas
|
|
DK1896071T3
(en)
|
2005-06-30 |
2015-05-26 |
Janssen Biotech Inc |
Methods and compositions with increased therapeutic activity
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
US7846724B2
(en)
|
2006-04-11 |
2010-12-07 |
Hoffmann-La Roche Inc. |
Method for selecting CHO cell for production of glycosylated antibodies
|
|
KR20090027227A
(ko)
*
|
2006-06-06 |
2009-03-16 |
제넨테크, 인크. |
항-ｄｌｌ4 항체 및 이의 사용 방법
|
|
US8580511B2
(en)
*
|
2006-06-19 |
2013-11-12 |
The Regents Of The University Of California |
Two-color fluorescent reporter for alternative pre-mRNA splicing
|
|
US7777008B2
(en)
|
2006-06-19 |
2010-08-17 |
Tolerx, Inc. |
ILT3 binding molecules and uses therefor
|
|
US7833260B2
(en)
|
2006-07-20 |
2010-11-16 |
Orbusneich Medical, Inc. |
Bioabsorbable polymeric medical device
|
|
ES2516694T3
(es)
*
|
2006-07-21 |
2014-10-31 |
Ratiopharm Gmbh |
Glicosilación de péptidos a través de secuencias de glicosilación con unión en O
|
|
US20100041872A1
(en)
|
2006-10-04 |
2010-02-18 |
Defrees Shawn |
Glycerol linked pegylated sugars and glycopeptides
|
|
CA2666308C
(en)
*
|
2006-10-26 |
2014-09-23 |
The Rockefeller University |
Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
|
|
FI20060946A0
(fi)
|
2006-10-26 |
2006-10-26 |
Glykos Finland Oy |
Influenssaviruksen nukleiinihappoja ja peptidejä
|
|
CL2007003411A1
(es)
*
|
2006-11-28 |
2008-07-04 |
Centelion |
Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu
|
|
CN101636168B
(zh)
|
2007-01-09 |
2013-05-29 |
比奥根艾迪克Ma公司 |
Sp35抗体及其用途
|
|
EP2125893A2
(en)
|
2007-01-23 |
2009-12-02 |
Xencor, Inc. |
Optimized cd40 antibodies and methods of using the same
|
|
EP2144628B1
(en)
|
2007-05-08 |
2012-10-17 |
Genentech, Inc. |
Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
|
|
DK2205258T3
(en)
*
|
2007-09-28 |
2017-08-28 |
Janssen Biotech Inc |
Method and structural conformations of antibody preparations with increased resistance to proteases
|
|
EP2050764A1
(en)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Novel polyvalent bispecific antibody format and uses thereof
|
|
MX2010003718A
(es)
|
2007-10-19 |
2010-04-21 |
Genentech Inc |
Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo.
|
|
CA2711503A1
(en)
*
|
2008-01-08 |
2009-07-16 |
Biogenerix Ag |
Glycoconjugation of polypeptides using oligosaccharyltransferases
|
|
SG187517A1
(en)
|
2008-01-31 |
2013-02-28 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
|
CN102105582A
(zh)
|
2008-04-21 |
2011-06-22 |
诺沃-诺迪斯克有限公司 |
高糖基化人凝血因子ix
|
|
UA40611U
(ru)
|
2008-05-26 |
2009-04-27 |
Владимир Семенович Живченко |
Способ десульфурации железоуглеродистого расплава в тигельной печи
|
|
AU2009288354A1
(en)
|
2008-08-26 |
2010-03-11 |
Macrogenics Inc. |
T-cell receptor antibodies and methods of use thereof
|
|
EP2233499A1
(en)
|
2009-03-26 |
2010-09-29 |
CSL Behring AG |
Antibody composition with altered Fab sialylation
|
|
US10087236B2
(en)
*
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
JP5826772B2
(ja)
|
2010-02-16 |
2015-12-02 |
ノヴォ ノルディスク アー／エス |
コンジュゲートタンパク質
|
|
JP5998060B2
(ja)
|
2010-03-04 |
2016-09-28 |
マクロジェニクス，インコーポレーテッド |
Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
|
|
WO2012020065A1
(en)
*
|
2010-08-10 |
2012-02-16 |
Glycotope Gmbh |
Fab-glycosylated antibodies
|
|
AR085302A1
(es)
*
|
2011-02-24 |
2013-09-18 |
Sanofi Sa |
Metodo de produccion de anticuerpos sialilados
|
|
CN103974619B
(zh)
|
2011-03-11 |
2017-02-15 |
阿米库斯治疗学公司 |
治疗法布里病的给药方案
|
|
TWI588156B
(zh)
|
2011-03-28 |
2017-06-21 |
賽諾菲公司 |
具有交叉結合區定向之雙重可變區類抗體結合蛋白
|
|
UY34317A
(es)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
Anticuerpo antireceptor de célula T (alfa)/ß
|
|
EA035987B1
(ru)
|
2012-09-12 |
2020-09-09 |
Джензим Корпорейшн |
ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ АФФИННОСТЬЮ К Fc-ГАММА РЕЦЕПТОРАМ
|
|
US9790268B2
(en)
|
2012-09-12 |
2017-10-17 |
Genzyme Corporation |
Fc containing polypeptides with altered glycosylation and reduced effector function
|
|
CN110256560A
(zh)
|
2013-03-11 |
2019-09-20 |
建新公司 |
通过糖工程的位点特异性抗体-药物偶联
|
|
PL3129067T3
(pl)
|
2014-03-19 |
2023-05-08 |
Genzyme Corporation |
Specyficzne dla miejsca glikomodyfikowanie ugrupowań celujących
|
|
CA2944539A1
(en)
|
2014-04-08 |
2015-10-15 |
University Of Georgia Research Foundation, Inc. |
Site-specific antibody-drug glycoconjugates and methods
|
|
PT3204425T
(pt)
|
2014-10-09 |
2020-12-18 |
Genzyme Corp |
Conjugados anticorpo fármaco glicomanipulados
|
|
MA55529A
(fr)
|
2019-04-03 |
2022-02-09 |
Genzyme Corp |
Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite
|